Amikacin

Essential medicine status ✓

Section: 6. Anti-infective medicines > 6.2. Antibacterials > 6.2.1. Access group antibiotics

ATC codes: J01GB06

Indication	Inflammatory and other diseases of prostate ICD11 code: GA91.Z
INN	Amikacin
Medicine type	Chemical agent
Antibiotic groups	A ACCESS
List type	Core
Formulations	Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
EML status history	First added in 2017 (TRS 1006) Changed in 2023 (TRS 1049)
Sex	Male
Age	Adolescents and adults
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Wikipedia	Amikacin
DrugBank	Amikacin

Expert Committee recommendation

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of a new strength formulation of amikacin (injection 50 mg/mL (as sulfate) in 2 mL vial) to the EMLc. - the addition of new strength formulations of cefotaxime (powder for injection: 500 mg; 1 g; 2 g (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ceftriaxone (powder for injection: 500 mg (as sodium) in vial) to the EML and EMLc. - the addition of a new strength formulation of ciprofloxacin (solid oral dosage form 100 mg (as hydrochloride)) to the EMLc.

EML recommendations: Inflammatory and other diseases of prostate

First choice	Second choice
MILD TO MODERATE	
ciprofloxacin	ceftriaxone
	cefotaxime
SEVERE	

ceftriaxone

co-prescribed with amikacin

cefotaxime

co-prescribed with amikacin